Simfibrate

Simfibrate

SCHEMBL27667

CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCCOC(=O)C(C)(C)Oc1ccc(Cl)cc1

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 5/20 0.74
CYP1A2 P05177 4/20 0.74
CYP3A4 P08684 4/20 0.74
ABCB11 O95342 2/20 0.74
TSHR P16473 2/20 0.74
HTR2A P28223 2/20 0.74
PMP22 Q01453 2/20 0.74
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
CYP2C19 P33261 3/20 0.60
MAPT P10636 2/20 0.60
CYP2D6 P10635 2/20 0.60
PPARG P37231 2/20 0.54
HPGD P15428 2/20 0.54
CYP2C9 P11712 2/20 0.54
USP2 O75604 1/20 0.54
LMNA P02545 1/20 0.54
ADORA3 P0DMS8 1/20 0.54
ADRB3 P13945 1/20 0.54
CNR1 P21554 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30231731 0.94 PPARA (0.75) PPARACYP1A2CYP3A4ABCB11TSHR
SCHEMBL2615467 0.93 PPARA (0.65) PPARACYP1A2CYP3A4ABCB11TSHR
SCHEMBL28102603 0.91 PPARA (0.67) PPARACYP1A2CYP3A4ABCB11TSHR
SCHEMBL28102602 0.90 PPARA (0.65) PPARACYP1A2CYP3A4ABCB11TSHR
SCHEMBL11641659 0.89 PPARA (0.72) PPARACYP1A2CYP3A4ABCB11TSHR
SCHEMBL11640865 0.89 PPARA (0.72) PPARACYP1A2CYP3A4ABCB11TSHR
SCHEMBL28882728 0.89 PPARA (0.63) PPARACYP1A2CYP3A4ABCB11TSHR
SCHEMBL11739630 0.88 PPARA (0.70) PPARACYP1A2CYP3A4ABCB11TSHR
SCHEMBL28102713 0.88 PPARA (0.70) PPARACYP1A2CYP3A4ABCB11TSHR
SCHEMBL12573937 0.87 PPARA (0.66) PPARACYP1A2CYP3A4ABCB11TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 4327 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680248-A1 PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM Topelia Aust Limited (ACN 652 771 670) (AU) 2026-01-21 EP claimed
US-20250269005-A1 METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT TOPELIA AUST LIMITED (ACN 652 771 670) (AU) 2025-08-28 US claimed
US-12377066-B2 Treatment of diseases associated with biliary system destruction ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (FR) 2025-08-05 US claimed
US-20250009744-A1 USE OF METABOLIC REGULATORS FOR THE TREATMENT OF LIPOTOXICITY IN THE LUNGS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2025-01-09 US claimed
WO-2024187239-A1 PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM TOPELIA AUST LIMITED (ACN 652 771 670) (AU) 2024-09-19 WO claimed
EP-4337179-A1 METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT Topelia Aust Limited (ACN 652 771 670) (AU) 2024-03-20 EP claimed
US-20240075049-A1 DRUGS, THERAPEUTIC COMBINATIONS AND METHODS FOR PREVENTING VIRAL AND MICROBIAL INFECTIONS AND THEIR SEQUELAE TOPELIA AUST LTD ACN 652 771 670 (AU) 2024-03-07 US claimed
EP-4322939-A1 USE OF METABOLIC REGULATORS FOR THE TREATMENT OF LIPOTOXICITY IN THE LUNGS Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) 2024-02-21 EP claimed
EP-4278190-A1 METHODS AND SYSTEMS OF IDENTIFYING INDIVIDUALS FOR PERIOPERATIVE NEUROCOGNITIVE DISORDER AND/OR POST-VIRAL COGNITIVE IMPAIRMENT Cambridge Cognition Limited (GB) 2023-11-22 EP claimed
US-20230360801-A1 METHODS AND SYSTEMS OF IDENTIFYING INDIVIDUALS FOR PERIOPERATIVE NEUROCOGNITIVE DISORDER AND/OR POST-VIRAL COGNITIVE IMPAIRMENT CAMBRIDGE COGNITION LIMITED (GB) 2023-11-09 US claimed
US-6133293-A INSULIN SENSITIVITY ENHANCER IN COMBINATION WITH OTHER ANTIDIABETICS DIFFERING FROM THE ENHANCER IN THE MECHANISM OF ACTION; POTENT DEPRESSIVE EFFECT ON DIABETIC HYPERGLYCEMIA; 2,4-THIAZOLIDINEDIONES AND OXAZOLIDINEDIONES TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2000-10-17 US claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
US-5811547-A Method for inducing crystalline state transition in medicinal substance NIPPON SHINYAJU CO., LTD. (JP) 1998-09-22 US claimed
US-5785976-A Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof PHARMACIA & UPJOHN AB (SE) 1998-07-28 US claimed
WO-1998031360-A1 PHARMACEUTICAL COMPOSITION HAVING HIGH BIOAVAILABILITY AND METHOD FOR PREPARING IT PHARMA PASS (FR) 1998-07-23 WO claimed
EP-0687172-A1 SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF Pharmacia & Upjohn Aktiebolag (SE) 1995-12-20 EP claimed
WO-1994020072-A1 SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF PHARMACIA AB (SE) 1994-09-15 WO claimed
US-5288503-A WATER-PERMEABLE DIFFUSION BARRIER OF POLYVINYL ALCOHOL SRCHEM INCORPORATED (US) 1994-02-22 US claimed
US-5260066-A Cryogel bandage containing therapeutic agent SRCHEM INCORPORATED (US) 1993-11-09 US claimed
US-4250191-A ADMINISTERING A PHENOXYACETIC ACID DERIVATIVE EDWARDS K DAVID 1981-02-10 US claimed